Two Natural Cap
Subscribe
Sign in
Home
Archive
About
UniQure: (Hopefully) Progress on miRNA Therapeutics $qure
siRNA vs miRNA, the FDA, Exon 1 vs Allele-Specific
Nov 6
•
Two Natural Capital
2
Latest
Top
Discussions
Capstan Therapeutics: LNP Delivery Beyond the Liver $abbv
In-vivo CAR-T, Targeted LNPs, and Autoimmune Disease
Oct 7
•
Two Natural Capital
1
MaxCyte: Powering Ex-Vivo Gene Editing $mxct
Casgevy, Allogeneic CAR-T, and Electroporation Technology
Sep 4
•
Two Natural Capital
3
Maravai: Can an mRNA Capping Provider Move Beyond Covid? $mrvi
mRNA, Biologics Safety Testing, and Cell/Gene Therapy
Jul 25
•
Two Natural Capital
2
CAR-T Therapy: How Can CRISPR Help?
Donors Cells, Immune System Evasion, AvenCell/Intellia/CRISPR Therapeutics
Jun 25
•
Two Natural Capital
1
CRISPR Comes Back to Life
Baby KJ, LNPs, and Danaher
Jun 11
•
Two Natural Capital
1
Casey’s General Stores: A Dollar General Approach to Gas Stations $casy
Pizza, Buc-ee’s, Expansion, and Zyn
May 7
•
Two Natural Capital
4
In Situ Sequencing: 10x Genomics, NanoString, and Vizgen $txg $brkr
Lawsuits, Sensitivity/Specificity, and Mouse Brains
Apr 25
•
Two Natural Capital
2
See all
Two Natural Cap
Writing about markets and life sciences; readers include investors from Baillie Gifford, GIC, and Susquehanna.
Subscribe
Recommendations
Owl Posting
Abhishaike Mahajan
Net Interest
Marc Rubinstein
White Noise
Tom White
Rough Diamonds
Sarah Constantin
Base by Base
Edward Larkin
Two Natural Cap
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
